In the past week, HCWB stock has gone down by -50.98%, with a monthly gain of 31.42% and a quarterly surge of 29.32%. The volatility ratio for the week is 33.49%, and the volatility levels for the last 30 days are 25.19% for HCW Biologics Inc The simple moving average for the past 20 days is 12.57% for HCWB’s stock, with a -33.83% simple moving average for the past 200 days.
Is It Worth Investing in HCW Biologics Inc (NASDAQ: HCWB) Right Now?
The 36-month beta value for HCWB is at 1.15. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for HCWB is 19.75M, and currently, shorts hold a 0.04% of that float. The average trading volume for HCWB on November 26, 2024 was 8.92M shares.
HCWB) stock’s latest price update
HCW Biologics Inc (NASDAQ: HCWB)’s stock price has dropped by -21.06 in relation to previous closing price of 0.77. Nevertheless, the company has seen a loss of -50.98% in its stock price over the last five trading days. globenewswire.com reported 2024-11-18 that MIRAMAR, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) — HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 6,717,000 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced above market under Nasdaq rules.
HCWB Trading at 14.54% from the 50-Day Moving Average
After a stumble in the market that brought HCWB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.88% of loss for the given period.
Volatility was left at 25.19%, however, over the last 30 days, the volatility rate increased by 33.49%, as shares surge +34.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.30% upper at present.
During the last 5 trading sessions, HCWB fell by -50.98%, which changed the moving average for the period of 200-days by -46.68% in comparison to the 20-day moving average, which settled at $0.5400. In addition, HCW Biologics Inc saw -50.38% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for HCWB
Current profitability levels for the company are sitting at:
- -10.61 for the present operating margin
- 0.18 for the gross margin
The net margin for HCW Biologics Inc stands at -10.68. The total capital return value is set at 10.58. Equity return is now at value -537.24, with -120.09 for asset returns.
Based on HCW Biologics Inc (HCWB), the company’s capital structure generated -1.75 points at debt to capital in total, while cash flow to debt ratio is standing at -2.41. The debt to equity ratio resting at -0.64. The interest coverage ratio of the stock is -96.83.
Currently, EBITDA for the company is -23.58 million with net debt to EBITDA at -0.15. When we switch over and look at the enterprise to sales, we see a ratio of 8.1. The receivables turnover for the company is 5.36for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.07.
Conclusion
In conclusion, HCW Biologics Inc (HCWB) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
